The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Comparative Expression Studies To Identify Cellular Factors Promoting Hendra Virus Replication For A Comprehensive Understanding Of Hendra Virus Pathogenesis
Funder
National Health and Medical Research Council
Funding Amount
$374,619.00
Summary
Hendra virus (HeV) is an emerging pathogen indigenous to fruit bats. HeV is associated with limited outbreaks with high mortality in domesticated animals and humans. To advance the understanding of HeV-related pathogenesis, we will perform comparative studies in bat and human cell lines to recognise differences in virus-host cell interactions leading to a comprehensive understanding of the HeV life cycle and pathogenesis.
Harnessing Lipid-reactive Immunity To Combat Mycobacterium Tuberculosis Infection
Funder
National Health and Medical Research Council
Funding Amount
$341,458.00
Summary
Critcial to the survival of Mycobacterium tuberculosis, the causative agent of tuberculosis (TB) is its unique waxy (lipid)-rich cell wall. This proposal aims to target components of its cell wall to devlop novel therapeutic strategies. Specifically, the Australian-Singapore alliance will examine how the immune system "sees" lipid based antigens from M. tuberculosis, and then will ultimately use this information towards the devlopment of novel lipid-based vaccines.